Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer

RB1: a prototype tumor suppressor and an enigma

(2016) Nicholas J. Dyson   GENES & DEVELOPMENT

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

(2016) Todd M. Bauer et al.   Journal of Thoracic Oncology

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

(2016) Kumar Sanjiv et al.   Cell Reports

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data

(2015) Lynnette Fernandez-Cuesta et al.   GENOME BIOLOGY

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

(2015) Rosaria Chilà et al.   Oncotarget

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma

(2015) Enrico Derenzini et al.   Oncotarget

Small cell lung cancer: Where do we go from here?

(2014) Lauren Averett Byers et al.   CANCER

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

CD74-NRG1 Fusions in Lung Adenocarcinoma

(2014) L. Fernandez-Cuesta et al.   Cancer Discovery

A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC

(2014) F. Dietlein et al.   Cancer Discovery

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) M. Fruh et al.   ANNALS OF ONCOLOGY

Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis

(2013) Demetrios Simos et al.   Clinical Lung Cancer

Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response

(2013) H. Christian Reinhardt et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular mechanisms underlying RB protein function

(2013) Frederick A. Dick et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors

(2013) A. Riabinska et al.   Science Translational Medicine

A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo

(2013) Sandra Morandell et al.   Cell Reports

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

(2012) M. C. Pietanza et al.   CLINICAL CANCER RESEARCH

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

The p53 network: cellular and systemic DNA damage responses in aging and cancer

(2012) H. Christian Reinhardt et al.   TRENDS IN GENETICS

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

(2012) E Fokas et al.   Cell Death & Disease

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication

(2011) C. S. Sorensen et al.   NUCLEIC ACIDS RESEARCH

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

(2010) H. Christian Reinhardt et al.   MOLECULAR CELL

Continued lack of progress in SCLC

(2010) Janakiraman Subramanian et al.   Nature Reviews Clinical Oncology

Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2

(2009) H Christian Reinhardt et al.   CURRENT OPINION IN CELL BIOLOGY

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

Cytokine-Induced Signaling Networks Prioritize Dynamic Range over Signal Strength

(2008) Kevin A. Janes et al.   CELL

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS